Encysive’s Thelin Gets EU Nod Ahead Of U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
EU marketing authorization of the pulmonary arterial hypertension treatment follows Encysive’s receipt of a second “approvable” letter for sitaxentan sodium from FDA.
You may also be interested in...
Thelin's Third "Approvable" Letter Recommends Additional Clinical Trial
Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.
Thelin's Third "Approvable" Letter Recommends Additional Clinical Trial
Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.
Encysive Thelin Approval Could Come Days Ahead Of Gilead’s Ambrisentan
FDA’s regulatory timeline for reviewing the two pulmonary arterial hypertension medications may fall neck and neck.